Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun;31(3):147-153.
doi: 10.1097/MOL.0000000000000680.

Apolipoprotein C-II: the re-emergence of a forgotten factor

Anna Wolska  1 , Mart Reimund  2 , Alan T Remaley  1
Affiliations
Review

Apolipoprotein C-II: the re-emergence of a forgotten factor

Anna Wolska et al. Curr Opin Lipidol. 2020 Jun.

Abstract

Purpose of review: Apolipoprotein C-II (apoC-II) is a critical cofactor for the activation of lipoprotein lipase (LPL), a plasma enzyme that hydrolyzes triglycerides (TG) on TG-rich lipoproteins (TRL). Although apoC-II was first discovered nearly 50 years ago, there is renewed interest in it because of the recent efforts to develop new drugs for the treatment of hypertriglyceridemia (HTG). The main topic of this review will be the development of apoC-II mimetic peptides as a possible new therapy for cardiovascular disease.

Recent findings: We first describe the biochemistry of apoC-II and its role in TRL metabolism. We then review the clinical findings of HTG, particularly those related to apoC-II deficiency, and how TG metabolism relates to the development of atherosclerosis. We next summarize the current efforts to develop new drugs for HTG. Finally, we describe recent efforts to make small synthetic apoC-II mimetic peptides for activation of LPL and how these peptides unexpectedly have other mechanisms of action mostly related to the antagonism of the TG-raising effects of apoC-III.

Summary: The role of apoC-II in TG metabolism is reviewed, as well as recent efforts to develop apoC-II mimetic peptides into a novel therapy for HTG.

PubMed Disclaimer

References

    1. Nordestgaard BG. TG-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ Res 2016; 118:547–563.
    1. Toth PP. TG-rich lipoproteins as a causal factor for cardiovascular disease. Vasc Health Risk Manag 2016; 12:171–183.
    1. Olivecrona G. Role of lipoprotein lipase in lipid metabolism. Curr Opin Lipidol 2016; 27:233–241.
    1. Wolska A, Dunbar RL, Freeman LA, et al. Apolipoprotein C-II: new findings related to genetics, biochemistry, and role in TG metabolism. Atherosclerosis 2017; 267:49–60.
    1. Brown WV, Levy RI, Fredrickson DS. Further characterization of apolipoproteins from the human plasma very low density lipoproteins. J Biol Chem 1970; 245:6588–6594.

Publication types

MeSH terms